The lead vaccine candidate of Advaxis.

Advaxis announces Phase We trial outcomes of its ADXS11-001 therapeutic cancer vaccine The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. The patients acquired participated in the 1st human being trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer tumor in women who’ve failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at three month intervals. Related StoriesNew vaccine appears to be more effective in reducing 'bad' LDL cholesterolMD Anderson study reveals why chemotherapy medications not effective for most pancreatic malignancy patientsCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesThese mortality figures substantially go beyond the median survival rate set up by the National Cancer tumor Institute’s Gynecologic Oncology Group , which varies between 3.8 and 6.2 months in studies of individuals who’ve failed prior cytotoxic treatment including chemotherapy with different agents .Evans is normally a Fellow of the American University of Medical Informatics .

Charlotte J. Haug, M.D., Ph.D.1 The retractions came only a few months after BioMed Central, an open-access publisher owned by Springer, retracted 43 articles for the same reason. How can you really fake peer review? Moon, who studies medicinal plants, had set up a straightforward procedure. He gave journals recommendations for peer reviewers for his manuscripts, providing them with names and e-mail addresses. But these addresses were ones he created, so the requests to review went directly to him or his co-workers.